<DOC>
	<DOCNO>NCT02419612</DOCNO>
	<brief_summary>This clincial trial evaluate co-administration saxagliptin dapagliflozin , addition metformin , result well glycemic control , measure HbA1c , treatment period 52 week , compare addition glimepiride metformin subject Type 2 Diabetes Mellitus inadequate glycemic control Metformin Alone . We compare change baseline HbA1c achieve saxagliptin , co-administration dapagliflozin , add current background therapy metformin compare glimepiride add current background therapy metformin ≥1500 mg Week 52 .</brief_summary>
	<brief_title>A 52-week International , Multicenter Trial With Long -Term Extension Evaluate Saxagliptin With Dapagliflozin Combination With Metformin Compared Glimepiride Combination With Metformin Type 2 Diabetes Who Have Inadequate Glycemic Control Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects must willing able give sign date write informed consent Patients Type 2 diabetes mellitus ( T2DM ) inadequate glycemic control Subjects take daily dose metformin ≥ 1500 mg Fasting Plasma Glucose ≤ 270 mg/dL ( ≤15 mmol/L ) Males female , age ≥18 year old time screen visit Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test WOCBP male must agree follow instruction method ( ) contraception duration treatment study drug Clinical diagnosis type I diabetes History diabetic ketoacidosis Cardiovascular/vascular disease within 3 month enrollment Renal disease Hepatic diseases History , currently , acute chronic pancreatitis Hematological oncological disease/conditions Patients contraindication therapy studied Patients weight loss program ( ) Replacement chronic systemic corticosteroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>